{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:41:09Z","timestamp":1793868069219,"version":"4.6.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"25","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Lipoprotein apheresis (LA) is the only approved treatment for patients with elevated lipoprotein(a) [Lp(a)]. The Lp(a)FRONTIERS APHERESIS trial investigated whether pelacarsen reduces the need for LA in patients from Germany with elevated Lp(a) and established cardiovascular disease (CVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with Lp(a) levels &amp;gt;60 mg\/dl who had undergone \u226535 LA sessions in the prior year were randomized to receive pelacarsen 80 mg or placebo every 4 weeks for 52 weeks. Weekly LA sessions were performed if the Lp(a) measurement from the prior visit was &amp;gt;60 mg\/dL. The primary endpoint was the rate of performed LA sessions normalized to the weekly LA schedule (the number of actual LA sessions divided by the number of planned LA sessions during the 52-week period). Secondary endpoints were time to LA avoidance (for \u226524 consecutive weeks) and total LA avoidance from week 12 to week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-one patients were randomized (mean age 61.7 years, mean Lp(a) at baseline 85.4 mg\/dL, and mean 44.0 LA sessions in the past 12 months), with 25 of 26 (96.2%) in the pelacarsen arm and 23 of 25 (92.0%) in the placebo arm completing the study. Baseline characteristics were generally balanced between treatment arms. Pelacarsen reduced the mean rates of LA (0.16 vs 0.93 in placebo, odds ratio 0.006, 95% confidence interval [CI] 0.003, 0.013; P &amp;lt; .0001) and substantially increased the hazard of achieving LA avoidance (hazard ratio: 88.3; P = .0014; median time to achieve LA avoidance: 6.1 weeks) and total LA avoidance (odds ratio: 163.2; P = .0005). The placebo-adjusted Lp(a) change from baseline at week 52 was \u221272% (95% CI: \u221279%, \u221261%; P &amp;lt; .0001). Treatment emergent adverse events were similar between arms, except for mostly mild injection site erythema (pelacarsen 38.5%; placebo 0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pelacarsen is a highly effective and well-tolerated Lp(a)-targeted therapy that substantially reduces the need for LA in patients with elevated Lp(a) and established CVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov, identifier<\/jats:title>\n                    <jats:p>NCT05305664.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag073","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:43:48Z","timestamp":1769690628000},"page":"3284-3294","source":"Crossref","is-referenced-by-count":13,"title":["Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-0412","authenticated-orcid":false,"given":"Klaus G","family":"Parhofer","sequence":"first","affiliation":[{"name":"Department of Medicine IV\u2014Grosshadern, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Julius","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Dresden at the Technische Universit\u00e4t Dresden , Dresden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-8964","authenticated-orcid":false,"given":"Anna Laura","family":"Herzog","sequence":"additional","affiliation":[{"name":"Transplantation Center, Department of Nephrology, University Hospital Wuerzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-5914","authenticated-orcid":false,"given":"Thilo","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"DaVita Clinical Research Germany , Duesseldorf ,","place":["Germany"]},{"name":"Department of Nephrology and Clinical Immunology, Uniklinik of the RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-8381","authenticated-orcid":false,"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I and Research Center of Immunotherapy, University Medical Center Mainz , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8320-5260","authenticated-orcid":false,"given":"Gunnar H","family":"Heine","sequence":"additional","affiliation":[{"name":"AGAPLESION MARKUS KRANKENHAUS Medical Department II, , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Schorr","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ferber","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8873-1198","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-1553","authenticated-orcid":false,"given":"Enrico","family":"Cristante","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8436-3591","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"M\u00fcller-Edenborn","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-1807","authenticated-orcid":false,"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-6377","authenticated-orcid":false,"given":"Volker","family":"Schettler","sequence":"additional","affiliation":[{"name":"Center of Nephrology G\u00f6ttingen GbR , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Lipid Clinic, Charite-Universit\u00e4tsmedizin Berlin , Augustenburger Platz I, 13353 Berlin ,","place":["Germany"]},{"name":"Department of Clinical Chemistry, Lipid Clinic Universit\u00e4tsmedizin Rostock, Ernst Heydemann Str. 5, 18057 Rostock ,","place":["Germany"]},{"name":"Friede Springer Cardiovascular Prevention Center, Charite-Universit\u00e4tsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"2026063019565809900_ehag073-B1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00392-024-02427-0","article-title":"Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients\u2014results from a large-scale multicentre registry in Germany","volume":"115","author":"Altmann","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"2026063019565809900_ehag073-B2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm\u20142020 Executive Summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"key":"2026063019565809900_ehag073-B3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026063019565809900_ehag073-B4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"2026063019565809900_ehag073-B5","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2026063019565809900_ehag073-B6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026063019565809900_ehag073-B7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026063019565809900_ehag073-B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026063019565809900_ehag073-B9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"key":"2026063019565809900_ehag073-B10","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026063019565809900_ehag073-B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11789-019-00094-4","article-title":"Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels","volume":"14","author":"Schettler","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"2026063019565809900_ehag073-B12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"2026063019565809900_ehag073-B13"},{"key":"2026063019565809900_ehag073-B14","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026063019565809900_ehag073-B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/1744-9987.13780","article-title":"The German Lipoprotein Apheresis Registry-Summary of the ninth annual report","volume":"26 Suppl 1","author":"Schettler","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2026063019565809900_ehag073-B16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa190523917","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026063019565809900_ehag073-B17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/(SICI)1099-1255(199611)11:6&lt;619::AID-JAE418&gt;3.0.CO;2-1","article-title":"Econometric methods for fractional response variables with an application to 401 (K) plan participation rates","volume":"11","author":"Papke","year":"1996","journal-title":"J App Econometrics"},{"key":"2026063019565809900_ehag073-B18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"2026063019565809900_ehag073-B19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2307\/2336190","article-title":"A stagewise rejective multiple test procedure based on a modified Bonferroni test","volume":"75","author":"Hommel","year":"1988","journal-title":"Biometrika"},{"key":"2026063019565809900_ehag073-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.01921","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"2026063019565809900_ehag073-B21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bcp.12961","article-title":"Injection site reactions after subcutaneous oligonucleotide therapy","volume":"82","author":"van Meer","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2026063019565809900_ehag073-B22","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"2026063019565809900_ehag073-B23","doi-asserted-by":"publisher","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/25\/3284\/67063642\/ehag073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/25\/3284\/67063642\/ehag073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:38:35Z","timestamp":1782909515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/25\/3284\/8494384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":23,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2026,2,21]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag073","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,1]]},"published":{"date-parts":[[2026,2,21]]}}}